Advanced or Metastatic Soft Tissue Sarcomas (STS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook

Thelansis’s “Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Soft Tissue Sarcomas (STS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic Soft Tissue Sarcomas (STS) Overview

Soft tissue sarcomas (STS), aggressive mesenchymal-origin tumors, represent 1% of all adult malignancies, with the World Health Organization recognizing over 50 distinct histological subtypes. Currently, the primary treatment strategy for localized STS involves surgery, optionally supplemented with perioperative chemotherapy. For patients with advanced or metastatic STS, the first-line treatment typically consists of palliative anthracycline-based chemotherapy administered either alone or in combination with ifosfamide. This applies to most STS subtypes. STS is known for their aggressive nature and propensity to infiltrate deep tissues. They exhibit a high recurrence rate of 35%, and in 16% of all cases, metastasis is already present at the time of diagnosis, predominantly affecting the lungs. The Overall Survival (OS) for patients with advanced metastatic STS is approximately 12 months. However, recent studies involving newer drugs have extended OS to 18 months. Interestingly, a subset of patients with metastatic STS can remain asymptomatic for extended periods, even in the absence of active treatment.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Advanced or Metastatic Soft Tissue Sarcomas (STS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034